Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript
…
0,954$
2,91%
Echtzeit-Aktienkurs Fate Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Fate Therapeutics Inc. Aktie
Sage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Call Transcript
…
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.…
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing…
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company…
Fate Therapeutics prices stock offering at $5.50 per share By Investing.com
Fate Therapeutics prices stock offering at $5.50 per share…
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript
…
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.…